Parnassus Endeavor Fund ABT trades
Parnassus Investments
Parnassus Endeavor Fund Abbott Laboratories stake
total: 118
Trades details
- Total transactions:
- 4
- New positions:
- 1
- Added:
- 3
- Held since:
- 2025 Q3
- Held for:
- 4 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Parnassus Endeavor Fund holds 645,227 Abbott Laboratories (ABT) shares with a market value of roughly $58.55M accounting for 1.11% of the overall portfolio. To date, the estimated cost basis is nearly $131.07 for "buy" trades. Parnassus Endeavor Fund first purchased ABT in 2025 Q3, initially acquiring 524,454 shares. Since the initial investment in Abbott Laboratories (ABT), Parnassus Endeavor Fund has made 3 more transactions.
When did Parnassus Endeavor Fund buy Abbott Laboratories (ABT)?
Parnassus Endeavor Fund first invested in Abbott Laboratories (ABT) in 2025 Q3 at the reported quarter-end price of $133.94 per share.
What's the cost basis of Parnassus Endeavor Fund's ABT stake?
The estimated cost basis for Abbott Laboratories (ABT) stake is around $131.07 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $131.07
Parnassus Endeavor Fund's historical trades in Abbott Laboratories
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
1.11%
|
645,227
|
$90.74
|
$58,547,898
|
+1.41% (+8,980)
|
+0.02%
|
|
2026 Q1
|
1.41%
|
636,247
|
$102.67
|
$65,323,479
|
+3.56% (+21,848)
|
+0.05%
|
|
2025 Q4
|
1.62%
|
614,399
|
$125.29
|
$76,978,051
|
+17.15% (+89,945)
|
+0.24%
|
|
2025 Q3
|
1.49%
|
524,454
|
$133.94
|
$70,245,369
|
new
|
+1.49%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.